Cover: Prescribing in primary care

Prescribing in primary care

Understanding what shapes GPs' prescribing choices and how might these be improved

Published May 12, 2007

by Amanda Watt, Jan Tiessen, Tom Ling, Lila Rabinovich

Download eBook for Free

Full Document

FormatFile SizeNotes
PDF file 0.6 MB

Use Adobe Acrobat Reader version 10 or higher for the best experience.

Summary Only

FormatFile SizeNotes
PDF file 0.2 MB

Use Adobe Acrobat Reader version 10 or higher for the best experience.

The National Audit Office (NAO) asked RAND Europe to conduct a qualitative study into general practitioners’ (GPs) prescribing behaviors. This study aims to understand what shapes GPs’ prescribing decisions, and how the cost efficiency of prescribing might be improved in the future. This qualitative study contributes to the NAO’s larger investigation into primary care prescribing in England, and more specifically how financial savings can be delivered by helping GPs deliver better value to patients. The approach used in RAND Europe’s study consisted of initial desk-based research and selection of two primary care trusts (PCTs), each representing cases with relatively low and high adherence to the National Institute of Health and Clinical Excellence (NICE) guidance on the prescribing of statins, which was taken as a proxy for prescribing efficiency. Within each PCT we conducted interviews with PCT managers, GP focus groups, and a workshop with GPs and other knowledgeable individuals. These forums were used to examine the current practice of GP prescribing, influences on GP prescribing decisions, and practical steps that could be taken to improve the cost efficiency of prescribing at the GP and PCT levels. RAND Europe’s work identified three areas for improvement: (1) the local level of the GP practice is important to foster a culture of inquiry and interest in new treatments alongside readily available cost information at the point of prescribing; (2) the regional level is important as a vehicle for translating scientific and cost information from general, possibly abstract, guidelines into information that is directly relevant to patients at the local level; and (3) experimental medicine conducted at national and international levels continues to be important to generate clear findings for possible use in developing guidelines.

Research conducted by

The research described in this report was prepared for the National Audit Office and was conducted by RAND Europe.

This report is part of the RAND technical report series. RAND technical reports may include research findings on a specific topic that is limited in scope or intended for a narrow audience; present discussions of the methodology employed in research; provide literature reviews, survey instruments, modeling exercises, guidelines for practitioners and research professionals, and supporting documentation; or deliver preliminary findings. All RAND reports undergo rigorous peer review to ensure that they meet high standards for research quality and objectivity.

This document and trademark(s) contained herein are protected by law. This representation of RAND intellectual property is provided for noncommercial use only. Unauthorized posting of this publication online is prohibited; linking directly to this product page is encouraged. Permission is required from RAND to reproduce, or reuse in another form, any of its research documents for commercial purposes. For information on reprint and reuse permissions, please visit

RAND is a nonprofit institution that helps improve policy and decisionmaking through research and analysis. RAND's publications do not necessarily reflect the opinions of its research clients and sponsors.